Tirzepatide vs Semaglutide: Weight Loss & Side Effects

Two Drugs, Different Receptor Strategies

By 2023, two injectable peptides dominated the obesity pharmacotherapy conversation — and they work differently enough that the comparison matters clinically. Semaglutide is a selective GLP-1 receptor agonist; tirzepatide is the first approved dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. That extra receptor target is why tirzepatide's weight loss numbers have surprised even its developers.

GIP receptors are expressed on adipocytes and in the central nervous system, and GIP agonism appears to amplify the satiety and thermogenic effects of GLP-1 activation. The mechanism is still being characterized, but the clinical data are unambiguous: tirzepatide consistently outperforms semaglutide on body weight reduction in head-to-head and parallel-design trials.

SURMOUNT vs. STEP: Reading the Trial Numbers

The SURMOUNT-1 trial (New England Journal of Medicine, 2022) enrolled 2,539 adults with obesity (BMI ≥30 or ≥27 with at least one weight-related comorbidity) but without type 2 diabetes. After 72 weeks, participants on tirzepatide 15 mg lost a mean 22.5% of body weight. The 10 mg dose produced 21.4% and the 5 mg dose 16.0%.

The STEP 1 trial (2021) with semaglutide 2.4 mg at 68 weeks showed mean weight loss of 14.9% in a similar population. That gap — roughly 7–8 percentage points at the highest doses — is clinically meaningful. Patients starting at 120 kg would lose approximately 27 kg on tirzepatide 15 mg versus 18 kg on semaglutide 2.4 mg.

HbA1c and Glycemic Control in Type 2 Diabetes

For patients with type 2 diabetes, tirzepatide's dual mechanism produces HbA1c reductions that exceed any other non-insulin drug class. The SURPASS-2 trial (2021) directly compared tirzepatide to semaglutide 1 mg (not the higher obesity dose) in 1,879 adults with type 2 diabetes. At 40 weeks, tirzepatide 15 mg reduced HbA1c by 2.46 percentage points versus 1.86 percentage points for semaglutide — a statistically significant difference. Weight loss was 12.4 kg vs. 6.2 kg.

The comparison is imperfect: semaglutide 1 mg is the standard diabetes dose, not the 2.4 mg obesity dose. No published trial has yet directly compared tirzepatide against semaglutide 2.4 mg. That gap in the evidence base is important context for any clinical decision.

• SURPASS-2: tirzepatide 15 mg reduced HbA1c by 2.46% vs. 1.86% for semaglutide 1 mg
• SURPASS-5: tirzepatide added to insulin glargine reduced HbA1c by 2.1–2.4%
• SURMOUNT-2: tirzepatide in obese patients with T2D showed 15.7% weight loss at 72 weeks

Cardiovascular Outcomes: Proven vs. Pending

Semaglutide has a substantial cardiovascular outcomes database. SUSTAIN-6 demonstrated 26% MACE reduction, SELECT (2023) showed 20% MACE reduction in non-diabetic obese patients — the first cardiovascular outcome trial in obesity without diabetes. These results established semaglutide's cardioprotective profile across multiple populations.

Tirzepatide's cardiovascular outcome data are pending. The SURPASS-CVOT trial is ongoing, expected to report in 2026. Based on SURPASS-2 results and mechanistic considerations, cardiologists expect a positive outcome, but prescribers relying on proven CV benefit must currently favor semaglutide. That evidence asymmetry may shift prescribing for high-risk patients.

Side Effect Profiles: More Similar Than Different

Both drugs share a GLP-1 mechanism, so their side effect profiles overlap substantially. The differences are modest and inconsistent across trials.

Tirzepatide may produce less nausea and vomiting than semaglutide at equivalent therapeutic exposures, possibly because GIP receptor co-agonism modulates nausea pathways. This is biologically plausible but not yet confirmed in prospective comparative trials designed to assess tolerability as a primary endpoint.

Cost, Access, and Availability

US list prices as of early 2025 place both drugs in the $900–$1,100/month range without insurance. Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) and semaglutide (Ozempic for diabetes, Wegovy for obesity) have separate FDA approvals across indications, which affects insurance coverage pathways.

Compounding pharmacies proliferated during the 2023–2025 shortage period, offering significantly cheaper versions of both drugs. The FDA removed semaglutide from the drug shortage list in February 2025, restricting compounded availability, while tirzepatide shortages continued into mid-2025 in several markets. Coverage for obesity indications (vs. diabetes) remains inconsistent across US insurance plans, with Medicare Part D's inclusion of anti-obesity drugs following the 2024 rule expansion affecting millions of patients' access.

This article is for informational purposes only. Consult a qualified healthcare professional.